Stanford Research Demonstrates Ultra-High Concentration Biologic Delivery via Subcutaneous Injection
Key Insights
Stanford University researchers published findings in Science Translational Medicine showing successful subcutaneous delivery of protein formulations exceeding 500 mg/mL through standard 27-gauge needles.
The spray-drying technology converts biologics (search) into microparticles suspended in liquid carriers, enabling stable, ready-to-inject solutions that meet viscosity requirements for subcutaneous administration.
Surf Bio (search)'s SnapShot™ platform leverages this breakthrough to transform infusion-only therapies into patient-friendly formulations compatible with standard autoinjectors and fill-finish processes.
Stanford University researchers have achieved a significant breakthrough in biologic drug delivery, demonstrating the feasibility of administering ultra-high concentration protein therapeutics through subcutaneous injection. The peer-reviewed study, published in Science Translational Medicine, shows that spray-dried microparticle formulations can exceed 500 mg/mL concentrations while maintaining deliverability through standard 27-gauge needles at clinically relevant forces.
The research, led by Dr. Carolyn Jons and collaborators, addresses a persistent challenge in modern therapeutics: enabling high-dose biologic therapies without requiring intravenous infusion. "Many existing protein-based therapies require hospital or clinic-based infusions due to their large volume, instability, or reconstitution requirements," stated Dr. Jons. "This study describes a spray-drying process that converts protein formulations into microparticles suspended in a non-solvent liquid carrier, resulting in a stable, ready-to-inject solution that meets the viscosity and force thresholds for subcutaneous administration."
Novel Formulation Technology
The published research, titled "Glassy Surfactants Enable Ultra-High Concentration Biologic Therapeutics," details a spray-drying process that transforms traditional protein formulations into injectable microparticle suspensions. The technology utilizes a proprietary polymer excipient that serves dual functions: improving stability during the spray-drying manufacturing process and enhancing the injectability of the final formulation.
In preclinical models, these microparticles demonstrated maintained protein activity and structural integrity while achieving doses substantially higher than those currently accessible with approved subcutaneous drug products. The formulations showed compatibility with commercially available autoinjectors and standard pharmaceutical fill-finish processes, eliminating the need for specialized delivery devices.
Clinical and Commercial Implications
Surf Bio (search), the biopharmaceutical company commercializing this technology through its SnapShot™ platform, views the publication as validation of their approach to transforming infusion-based therapies. "We're leveraging this licensed platform to help unlock subcutaneous administration for therapies that have historically required IV infusion," said Bryan Mazlish, CEO of Surf Bio. "Our goal is to translate this innovation into ready-to-inject, patient-friendly formulations that reduce burden on the healthcare system while enabling self-administration at home."
The technology platform enables development of ultra-high concentration formulations of monoclonal antibodies (search) and biologics (search) that can be administered through single, standard autoinjector shots. According to the company, in-vitro and in-vivo safety and efficacy data support the platform's ability to produce very high concentration, subcutaneous formulations of novel monoclonal antibodies and biologics.
Manufacturing and Delivery Advantages
The spray-drying approach offers several manufacturing benefits over traditional high-concentration biologic formulations. The process creates stable, ready-to-inject solutions that eliminate reconstitution requirements, a common barrier to subcutaneous delivery of concentrated biologics (search). The resulting formulations maintain appropriate viscosity profiles for injection through standard needles while preserving protein stability and bioactivity.
Surf Bio (search) was established by the founders of Bigfoot Biomedical (search) and AGC (search) to commercialize the breakthrough drug delivery technology originally developed in the Appel laboratory at Stanford University. The company's SnapShot technology platform is powered by their proprietary polymer system, designed specifically to enable ultra-high concentration biologic formulations suitable for subcutaneous delivery.